Goldman Sachs Maintains Tenet Healthcare(THC.US) With Hold Rating, Raises Target Price to $154
Tenet Healthcare Analyst Ratings
Morgan Stanley Raises Price Target on Tenet Healthcare to $175 From $165, Keeps Overweight Rating
Tenet Healthcare: Strong Performance and Growth Potential Justify Buy Rating Despite Lowered Price Target
RBC Capital Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $189
Truist Financial Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $175
UBS Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $230
Tenet Healthcare Is Maintained at Overweight by Barclays
Tenet Healthcare Price Target Raised to $171.00/Share From $161.00 by Barclays
Tenet Healthcare Is Maintained at Buy by UBS
Tenet Healthcare Price Target Raised to $230.00/Share From $217.00 by UBS
Tenet Healthcare Analyst Ratings
A Quick Look at Today's Ratings for Tenet Healthcare(THC.US), With a Forecast Between $165 to $185
Analysts Conflicted on These Healthcare Names: Tenet Healthcare (THC), Incyte (INCY) and Lemaitre Vascular (LMAT)
RBC Raises Price Target on Tenet Healthcare to $189 From $183, Keeps Outperform Rating
Tenet Healthcare's Strong Performance and Strategic Focus Justify Buy Rating
Research Alert: Thc Beats Q1 Eps Estimates As Patient Volumes And Favorable Mix Boost Margins
Baird Downgrades Tenet Healthcare to Neutral, Lowers Price Target to $137
RBC Capital Maintains Tenet Healthcare(THC.US) With Buy Rating, Cuts Target Price to $136
Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $161